

Figure 2. Kaplan-Meier survival curves based upon basal cytokeratin and HER1 staining. **A)** Kaplan-Meier disease-specific survival (DSS) curve for 829 tumours assessed for cytokeratin 5/6 and cytokeratin 17. **B)** Kaplan-Meier disease-specific survival (DSS) curve for 472 lymph node positive breast cancers assessed for cytokeratin 5/6 and cytokeratin 17. **C)** Kaplan-Meier disease-specific survival (DSS) curve for 210 lymph node negative breast cancers assessed for cytokeratin 5/6 and cytokeratin 17. **D)** Kaplan Meier disease-specific survival (DSS) curve in 609 breast cancers assessed for HER1 immunostaining.